These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 20564531)

  • 21. Probiotics for maintenance of remission in Crohn's disease.
    Rolfe VE; Fortun PJ; Hawkey CJ; Bath-Hextall F
    Cochrane Database Syst Rev; 2006 Oct; (4):CD004826. PubMed ID: 17054217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
    Yang C; Singh P; Singh H; Le ML; El-Matary W
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1079-93. PubMed ID: 25858208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omega Fatty Acids and Inflammatory Bowel Diseases: An Overview.
    Marton LT; Goulart RA; Carvalho ACA; Barbalho SM
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31574900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.
    Jeong DY; Kim S; Son MJ; Son CY; Kim JY; Kronbichler A; Lee KH; Shin JI
    Autoimmun Rev; 2019 May; 18(5):439-454. PubMed ID: 30844556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease.
    MacLean CH; Mojica WA; Newberry SJ; Pencharz J; Garland RH; Tu W; Hilton LG; Gralnek IM; Rhodes S; Khanna P; Morton SC
    Am J Clin Nutr; 2005 Sep; 82(3):611-9. PubMed ID: 16155275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining nutrition, food science and engineering in developing solutions to Inflammatory bowel diseases--omega-3 polyunsaturated fatty acids as an example.
    Ferguson LR; Smith BG; James BJ
    Food Funct; 2010 Oct; 1(1):60-72. PubMed ID: 21776456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives.
    Scaioli E; Liverani E; Belluzzi A
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials.
    Fujiya M; Ueno N; Kohgo Y
    Clin J Gastroenterol; 2014 Feb; 7(1):1-13. PubMed ID: 26183502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I interferons for induction of remission in ulcerative colitis.
    Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials.
    Shen J; Zuo ZX; Mao AP
    Inflamm Bowel Dis; 2014 Jan; 20(1):21-35. PubMed ID: 24280877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Park S; Abdi T; Gentry M; Laine L
    Am J Gastroenterol; 2016 Dec; 111(12):1692-1701. PubMed ID: 27725645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.
    Caviglia R; Ribolsi M; Rizzi M; Emerenziani S; Annunziata M; Cicala M
    World J Gastroenterol; 2007 Oct; 13(39):5238-44. PubMed ID: 17876895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
    Ford AC; Achkar JP; Khan KJ; Kane SV; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):601-16. PubMed ID: 21407188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review.
    Cabré E; Mañosa M; Gassull MA
    Br J Nutr; 2012 Jun; 107 Suppl 2():S240-52. PubMed ID: 22591898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease.
    Ng SC; Lam YT; Tsoi KK; Chan FK; Sung JJ; Wu JC
    Aliment Pharmacol Ther; 2013 Oct; 38(8):854-63. PubMed ID: 23981095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid treatment of inflammatory bowel disease.
    Endres S; Lorenz R; Loeschke K
    Curr Opin Clin Nutr Metab Care; 1999 Mar; 2(2):117-20. PubMed ID: 10453341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP; Marín AC; Chaparro M
    Am J Gastroenterol; 2016 May; 111(5):632-47. PubMed ID: 27002797
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.